Lymphatic vessel density and lymph node metastasis in prostate cancer

Authors

  • Yiping Zeng,

    1. Bernard O'Brien Institute of Microsurgery, Melbourne, Australia
    2. Department of Surgery, University of Melbourne, Melbourne, Australia
    Search for more papers by this author
  • Kenneth Opeskin,

    1. Department of Pathology, University of Melbourne, Melbourne, Australia
    2. Department of Anatomical Pathology, St. Vincent's Hospital, Melbourne, Australia
    Search for more papers by this author
  • Lisa G. Horvath,

    1. Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, Australia
    2. Cancer Research Program, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, Australia
    Search for more papers by this author
  • Robert L. Sutherland,

    1. Cancer Research Program, Garvan Institute of Medical Research, St. Vincent's Hospital, Sydney, Australia
    Search for more papers by this author
  • Elizabeth D. Williams

    Corresponding author
    1. Bernard O'Brien Institute of Microsurgery, Melbourne, Australia
    2. Department of Surgery, University of Melbourne, Melbourne, Australia
    • Bernard O'Brien Institute of Microsurgery, 42 Fitzroy Street, Fitzroy, Victoria 3065, Australia.
    Search for more papers by this author

Abstract

BACKGROUND

Few data are available examining the significance of prostatic lymphatic vessel density (LVD) to lymph node metastasis in patients with prostate cancer. The purpose of this study was to determine the distribution of lymphatic vessels in non-carcinomatous prostate tissue, and investigate the relationship between LVD and lymph node status in prostate cancer.

METHODS

LVD, identified by D2-40 immunostaining, was evaluated in non-carcinomatous prostates (n = 7) and prostate cancer (n = 37). The staining pattern of D2-40 was compared with that of another lymphatic vessel marker, vascular endothelial growth factor (VEGF) receptor-3, and a blood vessel endothelial marker, CD34, in adjacent sections.

RESULTS

The D2-40 antigen, podoplanin, was expressed exclusively in lymphatic vessels within tumor and normal tissue in all specimens. There was no overlap between cell staining for D2-40 and CD34. Peritumoral LVD and peritumoral lymphatic invasion were significantly associated with lymph node metastasis. VEGF receptor-3 was expressed in a subset of D2-40+ lymphatic vessels.

CONCLUSIONS

We have demonstrated that peritumoral lymphatic vessels are likely to serve as major conduits for nodal metastasis in prostate cancer using D2-40 to decorate lymphatic endothelium marker podoplanin. Lack of coexpression of podoplanin and VEGF receptor-3 in some lymphatic vessels suggests the heterogeneity of lymphatic endothelial cells in prostate tissue. © 2005 Wiley-Liss, Inc.

Ancillary